An evaluation of rectal mucosal proliferation measure variability sources in the polyp prevention trial: Can we detect informative differences among individuals' proliferation measures amid the noise?

Cancer Epidemiology Biomarkers and Prevention

Volumn 7, Issue 7, 1998, Pages 605-612

  McShane, Lisa M ^a   Kulldorff, Martin ^a   Wargovich, Michael J ^b   Woods, Cindy ^b   Purewal, Madhu ^b   Freedman, Laurence S ^a   Corle, Donald K ^a   Burt, Randall W ^c   Mateski, Donna J ^e   Lawson, Michael ^d   Lanza, Elaine ^a   O'Brien, Barbara ^f   Lake Jr , William ^g   Moler, James ^g   Schatzkin, Arthur ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d Kaiser Medical Center   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f WESTAT   (United States)

^g INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CYCLINE;

ARTICLE; CELL PROLIFERATION; COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECTUM BIOPSY; RECTUM MUCOSA; RECTUM POLYP; RELIABILITY;

ADULT; BIOPSY; BROMODEOXYURIDINE; CELL DIVISION; DOUBLE-BLIND METHOD; HUMANS; INTESTINAL MUCOSA; PROLIFERATING CELL NUCLEAR ANTIGEN; RECTUM; REPRODUCIBILITY OF RESULTS;

EID: 7344253533     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Einspahr, J G., Alberts. D S , Gapstur, S M., Bostick, R M , Emerson, S S , and Gemer, E W. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Cancer Epidemiol. Biomark. Prev., 6 37-48, 1997
2. Schatzkm. A , Freedman, L. S., Dorgan, J., McShane, L., Schrffman. M , and Dawsey, S. M. Surrogate endpoints in cancer research a critique (Editorial) Cancer Epidemiol. Biomark. Prev., 5: 947-953, 1996.
3. Baron, J A . Tosteson. T D., Waigovich, M. J , Sandler, R , Mandel, J., Bond, j , Haile, R , Summers, R., van Stolk, R., Rothstein, R., and Weiss, J Calcium supplementation and rectal mucosal proliferation a randomized controlled trial J Natl. Cancer Inst, 87: 1303-1307, 1995
4. Bostick, R. M , Fosdick, L., Wood, J. R., Grambsch, P., Grandits, G. A , Lillemoe, T. J , Louis, T. A , and Potter, J D. Calcium and colorectal epithelial cell proliferation in sporadic adenoma patients' a randomized, double-blinded, placebo-controlled clinical trial. J. Nail. Cancer Inst., 87. 1307-1315. 1995
5. Alberts, D S., Einspahr, J., Ritenbaugh, C., Aickin, M , Rees-McGee, S , Atwood, J., Emerson, S , Mason-Liddil, N., Bettinger, L., Patel, J., Bellapravalu, S., Ramanujam, P. S., Phelps, J , and Clark, L. The effect of wheat bran fiber and calcium supplementation on rectal mucosal proliferation rates in patients with resected adenomatous colorectal polyps. Cancer Epidemiol. Biomark Prev , 6. 161-169, 1997
6. Schatzkin, A , Lanza, E., Freedman, L S , Tangrea, J., Cooper, M. R , Marshall. J. R , Murphy, P. A , Selby, J. V , Shike, M., Schade, R. R., Burt, R. W., Kikendall, W., and Cahill, J. for the PPT Study Group. The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics Cancer Epidemiol Biomark. Prev., 5. 375-383, 1996
7. Lanza, E , Schatzkin, A., Ballard-Barbash, R , Corle, D., Clifford, C., Paskett, E , Hayes, D., Boté, E., Caan, B., Shike, M , Weissfeld, J., Slattery, M , Mateski, D., and Daston, C. for the PPT Study Group The polyp prevention trial II: dietary intervention program and participant baseline dietary characteristics Cancer Epidemiol Biomark. Prev., 5: 385-392, 1996.
8. Searle, S. R , Casella, G, and McCulloch, C E. Variance Components, pp 2-3 New York: John Wiley & Sons, Inc , 1992
9. h) labeling distribution as a marker for hereditary predisposition to colon cancer. Cancer Res , 43: 1899-1904, 1983
10. Grambsch, P., Louis, T. A., Bostick, R. M., Grandits, G A., Fosdick, L., Darif, M , and Potter, J. D Statistical analysis of proliferative index data in clinical trials. Stat. Med., 13: 1619-1634, 1994.
11. SAS Institute, Inc The mixed procedure. SAS Technical Report P-229: SAS/STAT Software Changes and Enhancements, pp. 287-366 Gary, NC SAS Institute, 1992.
12. Bostick, R. M . Potter, J D., Fosdick, L , Grambsch, P., Lampe, J. W , Wood, J. R., Louis, T A., Ganz, R., and Grandits, G. Calcium and colorectal epithelial cell proliferation a preliminary randomized, double-blinded, placebo-controlled clinical trial. J. Natl. Cancer Inst., 85. 132-141. 1993.
13. Lyles, C. M., Sandler, R. S , Keku, T. O , Kupper, L L , Millikan, R. C., Murray, S. C, Bangdiwala, S. I., and Ulshen, M. H. Reproducibility and variability of the rectal mucosal proliferation index using proliferating cell nuclear antigen immunohistochemistry. Cancer Epidemiol. Biomark. Prev., 3; 597-605, 1994.
14. Macrae, F. A., Kilias, D., Sharpe, K , Hughes, N , Young, G. P., MacLennan, R., and the Australian Polyp Prevention Project Investigators. Rectal epithelial cell proliferation: comparison of errors of measurement with inter-subject variance. J Cell Biochein Suppl., 19: 84-90, 1994
15. Einspahr, J., Alberts, D , Xie, T., Ritchie, J., Earnest, D , Hixson, L., Powell, M., Roe, D , and Grogan, T Comparison of proliferating cell nuclear antigen versus the more standard measures of rectal mucosal proliferation rates in subjects with a history of colorectal cancer and normal age-matched controls. Cancer Epidemiol Biomark. Prev , 4: 359-366, 1995.
16. Murray, S. C., Sandler, R S , Keku, T O., Lyles, C. M , Millikan, R C., Bangdiwala, S. I, Kupper, L. L., Jiang, W., and Ulshen, M H. Comparison of rectal mucosal proliferation measured by proliferating cell nuclear antigen (PCNA) immunohistoehemistry and whole crypt dissection Cancer Epidemiol. Biomark. Prev., 4. 715-720, 1995
17. Tosteson, T. D., Karagas, M R , Rothstein, R., Ahnen, D J., and Greenberg, E R. Reliability of whole crypt mitotic count as a measure of cellular proliferation in rectal biopsies Cancer Epidemiol. Biomark Prev., 5: 437-439, 1996
18. Boone, C. W , and Kelloff, G K (eds.). Quantitative pathology in chemoprevention trials: standardization and quality control of surrogate endpoint biomarker assays for colon, breast, and prostate J. Cell. Biochem Suppl, 19: 1-293, 1994.
19. Lipkin, M , and Newmark, H. Development of clinical chemoprevention trials (Editorial). J Natl. Cancer Inst, 87: 1275-1277, 1995,
20. Baron, J. A , Wargovich, M. J., Tosteson, T. D , Sandler, R., Haile, R , Summers, R., van Stolk, R, Rothstein, R., and Weiss, J. Epidemiological use of rectal proliferation measures. Cancer Epidemiol. Biomark. Prev , 4. 57-61, 1995.
21. Bostick. R. M , Fosdick, L., Lillemoe. T J., Overn, P, Wood, J. R., Grambsch, P., Elmer, P , and Potter, J D Methodologie findings and considerations in measuring colorectal epithelial cell proliferation in humans. Cancer Epidemiol Biomark. Prev , 6: 931-942, 1997.
22. Marra, G , Anti, M., Percesepe, A., Armelao, F, Ficarelli, R , Coco, C., Rinelli, A , Vecchio, F. M., D'Arcangelo, E Circadian variations of epithelial cell proliferation in human rectal crypts Gastroenterology, 106. 982-987, 1994.
23. Self, S. G., and Liang, K. Y. Asymptotic properties of maximum likelihood estimators and likelihood ratio tests under nonstandard conditions J. Am Stat. Assoc , 82: 605-610, 1987.
24. Morgan, E , and Gumpertz, M. Random effects models, testing whether variance components are zero. Proc Am. Slat Assoc Biom Sec, 118-126, 1997.
25. Pantula, S G Discussion on "likelihood ratio tests for variance components." Proc. Am. Stat Assoc Biom. Sec., 127-129, 1997.